Flora Peyvandi
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy · A.Bonomi Hemophilia and Thrombosis Center, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Flora Peyvandi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:45 UTC. Open this list on ClinicalTrials.gov
- N/ANCT07875478 · A Database For The Collection Of Clinical, Laboratory, And Treatment Data From Patients With Factor X Deficiency To Define The Natural History Of The Disease And Improve Patient ManagementFondazione Luigi Villa · recruiting · Factor X Deficiency · principal investigator
- N/ANCT06376786 · Italian iTTP RegistryFondazione Luigi Villa · recruiting · TTP - Thrombotic Thrombocytopenic Purpura · principal investigator
- N/ANCT05116501 · Genetic Background of Patients With Low Von Willebrand Factor LevelsFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · completed · Low Von Willebrand Factor · principal investigator
- N/ANCT03797495 · Study of Individuals Affected With HypoplasminogenemiaIndiana Hemophilia &Thrombosis Center, Inc. · recruiting · Plasminogen Deficiency · principal investigator
- Ph4NCT02479087 · Safety/Efficacy Study to Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance in Haemophilia A PatientsFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · unknown · Hemophilia A · study director
- Ph1/Ph2NCT02281500 · Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Participants With Congenital AfibrinogenemiaGrifols Therapeutics LLC · completed · Congenital Afibrinogenemia · study chair
- N/ANCT01949220 · Willebrand International Non-interventional Global SurveillanceLaboratoire français de Fractionnement et de Biotechnologies · completed · Von Willebrand Disease · study director
- Ph4NCT01064284 · Survey of Inhibitors in Plasma-Product Exposed ToddlersFondazione Angelo Bianchi Bonomi · completed · Hemophilia A · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:45 UTC. The ranking covers the 200 most relevant of 45 PubMed records, and a shared surname and initials can bring in a namesake. All 45 on PubMed
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.N Engl J Med · 2019807 citationsRCR 36.0
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.N Engl J Med · 2016521 citationsRCR 20.0
- 394 citationsRCR 16.7
- Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.N Engl J Med · 2023182 citationsRCR 18.0
- The bleeding score predicts clinical outcomes and replacement therapy in adults with von Willebrand disease.Blood · 2014121 citationsRCR 4.9
- Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.J Thromb Haemost · 201795 citationsRCR 3.6
- Pharmacokinetics and safety of fibrinogen concentrate.J Thromb Haemost · 200988 citationsRCR 3.4
- 86 citationsRCR 19.9
- 80 citationsRCR 4.7
- The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study.Haemophilia · 201972 citationsRCR 4.7